Albireo Pharma Inc (NASDAQ:ALBO) Expected to Post Earnings of -$1.55 Per Share

Wall Street brokerages forecast that Albireo Pharma Inc (NASDAQ:ALBO) will post ($1.55) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Albireo Pharma’s earnings. The lowest EPS estimate is ($1.72) and the highest is ($1.35). Albireo Pharma reported earnings per share of ($1.17) in the same quarter last year, which indicates a negative year-over-year growth rate of 32.5%. The business is scheduled to announce its next quarterly earnings report on Tuesday, November 12th.

On average, analysts expect that Albireo Pharma will report full year earnings of ($5.91) per share for the current year, with EPS estimates ranging from ($6.36) to ($5.43). For the next financial year, analysts anticipate that the business will post earnings of ($6.10) per share, with EPS estimates ranging from ($9.47) to ($4.43). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Albireo Pharma.

Albireo Pharma (NASDAQ:ALBO) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.35) EPS for the quarter, beating analysts’ consensus estimates of ($1.44) by $0.09. Albireo Pharma had a negative return on equity of 51.74% and a negative net margin of 2,403.88%. The firm had revenue of $1.25 million for the quarter, compared to the consensus estimate of $1.11 million.

ALBO has been the topic of a number of recent research reports. Wedbush restated an “outperform” rating and issued a $69.00 target price on shares of Albireo Pharma in a research note on Friday, August 9th. William Blair reaffirmed a “buy” rating on shares of Albireo Pharma in a research report on Monday, July 15th. BidaskClub raised Albireo Pharma from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 21st. ValuEngine raised Albireo Pharma from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 2nd. Finally, Zacks Investment Research cut Albireo Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Albireo Pharma currently has an average rating of “Buy” and an average target price of $51.50.

NASDAQ ALBO traded up $0.11 on Thursday, reaching $23.49. The stock had a trading volume of 52,881 shares, compared to its average volume of 47,571. The business has a 50 day moving average price of $24.41 and a 200 day moving average price of $30.11. Albireo Pharma has a 1 year low of $19.10 and a 1 year high of $38.69.

Several large investors have recently made changes to their positions in ALBO. Bank of America Corp DE lifted its stake in shares of Albireo Pharma by 87.6% in the 4th quarter. Bank of America Corp DE now owns 6,469 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 3,020 shares during the period. Federated Investors Inc. PA lifted its stake in shares of Albireo Pharma by 22.8% in the 1st quarter. Federated Investors Inc. PA now owns 719,595 shares of the biopharmaceutical company’s stock valued at $23,178,000 after purchasing an additional 133,449 shares during the period. Private Advisors LLC lifted its stake in shares of Albireo Pharma by 3.4% in the 1st quarter. Private Advisors LLC now owns 15,198 shares of the biopharmaceutical company’s stock valued at $490,000 after purchasing an additional 506 shares during the period. Marshall Wace North America L.P. acquired a new position in shares of Albireo Pharma in the 1st quarter valued at $816,000. Finally, Chicago Capital LLC lifted its stake in shares of Albireo Pharma by 6.8% in the 2nd quarter. Chicago Capital LLC now owns 202,241 shares of the biopharmaceutical company’s stock valued at $6,520,000 after purchasing an additional 12,833 shares during the period. 73.02% of the stock is owned by institutional investors.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Featured Story: Convertible Shares

Get a free copy of the Zacks research report on Albireo Pharma (ALBO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.